Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Kölbeck · SciRah

Researcher profile · Semantic Scholar

K. Kölbeck

Share profile

K. Kölbeck — researcher profile on SciRah

h-index: 10
Works: 32
Citations: 2,110

Most-cited papers

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Keunchil Park, E. Tan, K. O'Byrne, Li Zhang +19 more
2016The Lancet Oncology1,075 citations
Semantic Scholar
Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007
S. Walters, C. Maringe, M. Coleman, M. Peake +19 more
2013Thorax564 citations Open access
Semantic Scholar
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
C. Sederholm, G. Hillerdal, K. Lamberg, K. Kölbeck +3 more
2005Journal of Clinical Oncology174 citations Open access
Semantic Scholar
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
L. Paz-Ares, E. Tan, K. O'Byrne, L. Zhang +16 more
2017Annals of Oncology133 citations Open access
Semantic Scholar
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
M. Schuler, E. Tan, K. O'Byrne, Li Zhang +16 more
2019Journal of Cancer Research and Clinical Oncology36 citations Open access
Semantic Scholar
Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
Elsa Davidsson, N. Murgia, C. Ortiz-Villalón, Emil Wiklundh +3 more
2016Multidisciplinary Respiratory Medicine25 citations Open access
Semantic Scholar
Early symptoms and sensations as predictors of lung cancer: a machine learning multivariate model
A. Levitsky, M. Pernemalm, B. Bernhardson, J. Forshed +6 more
2019Scientific Reports22 citations Open access
Semantic Scholar
Quantitative assessment of 99mtc-depreotide uptake in patients with non-small-cell lung cancer: immunohistochemical correlations
G. Herlin, K. Kölbeck, P. Menzel, L. Svensson +3 more
2009Acta Radiologica20 citations
Semantic Scholar
Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
L. Paz-Ares, E. Tan, L. Zhang, V. Hirsh +16 more
201616 citations Open access
Semantic Scholar
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).
V. Hirsh, J. Yang, E. Tan, K. O'Byrne +16 more
201613 citations
Semantic Scholar
Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical Practice.
H. Koyi, G. Hillerdal, K. Kölbeck, Daniel Brodin +2 more
2016Anticancer Research8 citations Open access
Semantic Scholar
Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden
H. Koyi, G. Hillerdal, Olov Andersson, K. Kölbeck +2 more
2015Lung Cancer International7 citations Open access
Semantic Scholar
Optimizing diffusion-weighted magnetic resonance imaging for evaluation of lung tumors: A comparison of respiratory triggered and free breathing techniques
S. Swerkersson, O. Grundberg, K. Kölbeck, A. Carlberg +2 more
2018European Journal of Radiology Open6 citations Open access
Semantic Scholar
Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer: A prospective, single-arm, open-label, clinical trial (BevMar).
O. Grundberg, M. Skribek, S. Swerkersson, Mikael Skorpil +4 more
2024European Journal of Radiology3 citations Open access
Semantic Scholar
Using patients’ own knowledge of early sensations and symptoms to develop an interactive, individualized e-questionnaire to facilitate early diagnosis of lung cancer
A. Levitsky, B. Bernhardson, I. Henoch, M. Olin +4 more
2021BMC Cancer3 citations Open access
Semantic Scholar
[Pulmonary tularemia: rare disease that can be interpreted as lung cancer. Serology provides the correct diagnosis, as shown by case reports].
G. Hillerdal, K. Kölbeck, H. Jacobsson
2013Läkartidningen2 citations
Semantic Scholar
P1.06-008 Non-Small Cell Lung Cancer in Octogenarians: Real-Life Clinical Practice; Characteristics, Therapy and Survival: Topic: Advanced General
H. Koyi, G. Hillerdal, K. Kölbeck, Daniel Brodin +1 more
20171 citations Open access
Semantic Scholar
Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
V. Hirsh, Kyung-Ah Park, E. Tan, Li Zhang +16 more
20171 citations
Semantic Scholar
OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7
Keunchil Park, E. Tan, Li Zhang, V. Hirsh +16 more
20171 citations Open access
Semantic Scholar
440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
K. Park, E. Tan, Luan-Kun Zhang, V. Hirsh +16 more
20161 citations
Semantic Scholar
Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
M. Schuler, E. Tan, K. O'Byrne, L. Zhang +16 more
20161 citations Open access
Semantic Scholar
Using patients’ own knowledge of early sensations and symptoms to develop an interactive, individualized e-questionnaire to facilitate early diagnosis of lung cancer
A. Levitsky, B. Bernhardson, I. Henoch, M. Olin +4 more
2021BMC Cancer0 citations Open access
Semantic Scholar
P2.01-27 Apparent Diffusion Coefficient (ADC) Change on Repeated Diffusion-Weighted MRI During Chemotherapy for Stage IV Lung NSCLC
O. Grundberg, M. Skorpil, S. Swerkersson, K. Kölbeck +2 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
P2.13-02 ALK-Translocation and Brain Metastases: A Retrospective Study. Correlation Between Clinical Outcome, Disease Burden and Management.
O. Grundberg, S. Friesland, S. Abdel-Halim, S. Gagatek +9 more
2018Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
P2.03b-013 Outcome of Patients with ALK+ NSCLC and Brain Metastases in Relation to Disease Burden and Clinical Management: Topic: Brain Meta
L. De Petris, S. Friesland, Daniel Brodin, H. Carstens +9 more
20170 citations Open access
Semantic Scholar
P2.03a-013 Chemotherapy is Beneficial for Octogenarians with Non-Small Cell Lung Cancer (NSCLC): Topic: Clinical Trials
H. Koyi, G. Hillerdal, K. Kölbeck, Daniel Brodin +1 more
20170 citations Open access
Semantic Scholar
Surgery in Elderly Patients ( g 70 Years or Older) with Non-Small Lung Cancer (NSCLC). Impact of Adjuvant Chemotherapy
H. Koyi, G. Hillerdal, K. Kölbeck, Olov Andersson +4 more
20150 citations
Semantic Scholar
[Fast track assessment of lung cancer cut the investigation time in half].
K. Kölbeck, Susan Kamareji, H. Jacobsson, G. Hillerdal
2013Läkartidningen0 citations
Semantic Scholar
Pemetrexed plus gemcitabine versus gemcitabine plus carboplatin in patients with advanced nonoperable NSCLC: A randomized phase II study.
G. Hillerdal, H. Koyi, E. Brandén, K. Kölbeck
20100 citations
Semantic Scholar
Vasoactive Intestinal Peptide is a Potent Primer for Mast Cell Recruitment to the Allergic Airway: A Novelbiophysical Association of F-Actin
A. Ehnhage, P. Olsson, K. Kölbeck, Maria Skedinge +3 more
20090 citations
Semantic Scholar
Contribution of FDG-PET on staging and management of NSCLC planned for concomitant chemoradiotherapy: P1-059
Maria Diakopoulou, O. Brodin, K. Kölbeck
20070 citations
Semantic Scholar
P-349 The role of somatostatin-receptor-scintigraphy with 99m-Tc-depreotide(NeoSpect) in the diagnosis of lung cancer
M. Bååth, K. Kölbeck, U. Forslöw, R. Danielsson
20050 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. O'Byrne×9
Invite
K. O'Byrne — researcher profile on SciRah
M. Boyer×9
Invite
M. Boyer — researcher profile on SciRah
T. Mok×9
Invite
T. Mok — researcher profile on SciRah
V. Hirsh×9
Invite
V. Hirsh — researcher profile on SciRah

×9

Invite

L. Paz-Ares — researcher profile on SciRah

G. Hillerdal×9

Invite

G. Hillerdal — researcher profile on SciRah

Invite

E. Tan — researcher profile on SciRah

Invite

Shun Lu — researcher profile on SciRah

Yuan-Kai Shi×8

Invite

Yuan-Kai Shi — researcher profile on SciRah

Invite

J. Laskin — researcher profile on SciRah

Invite

K. Lee — researcher profile on SciRah

Invite

S. Laurie — researcher profile on SciRah